Immutep to Discontinue Lung Cancer Trial Over Results of Efficacy, Safety Data Review; Shares Hit All-Time Low
MT Newswires Live
Mar 13
Immutep (ASX:IMM) will discontinue its Tacti-004 phase 3 trial, following recommendation from the Independent Data Monitoring Committee, according to a Friday filing with the Australian bourse.
The committee's recommendation comes after a review of the available safety and efficacy data, per the filing.
The study was evaluating eftilagimod alfa in patients in first line non-small cell lung cancer, the filing said. In response to the committee's recommendation, the company will stop patient enrollment and wind down the study.
Immutep shares tumbled past 92% in recent Friday trade and earlier hit an all-time low.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.